These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34521624)

  • 1. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
    Paoletti C; Barlow WE; Cobain EF; Bergqvist M; Mehta RS; Gralow JR; Hortobagyi GN; Albain KS; Pusztai L; Sharma P; Godwin AK; Thompson AM; Hayes DF; Rae JM
    Clin Cancer Res; 2021 Nov; 27(22):6115-6123. PubMed ID: 34521624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer.
    Larsson AM; Bendahl PO; Aaltonen K; Jansson S; Forsare C; Bergqvist M; Jørgensen CLT; Rydén L
    Sci Rep; 2020 Mar; 10(1):4484. PubMed ID: 32161278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
    Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Kaufman B; Mackey JR; Clemens MR; Bapsy PP; Vaid A; Wardley A; Tjulandin S; Jahn M; Lehle M; Feyereislova A; Révil C; Jones A
    J Clin Oncol; 2009 Nov; 27(33):5529-37. PubMed ID: 19786670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with
    Gennari A; Brain E; De Censi A; Nanni O; Wuerstlein R; Frassoldati A; Cortes J; Rossi V; Palleschi M; Alberini JL; Matteucci F; Piccardo A; Sacchetti G; Ilhan H; D'Avanzo F; Ruffilli B; Nardin S; Monti M; Puntoni M; Fontana V; Boni L; Harbeck N;
    Ann Oncol; 2024 Jun; 35(6):549-558. PubMed ID: 38423389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
    Burstein HJ; Cirrincione CT; Barry WT; Chew HK; Tolaney SM; Lake DE; Ma C; Blackwell KL; Winer EP; Hudis CA
    J Clin Oncol; 2014 Dec; 32(35):3959-66. PubMed ID: 25348000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
    Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
    BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
    Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
    Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ;
    Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.